Sanofi India Limited has received a significant tax demand order from the Commercial Tax Officer in Tiruvalur, Tamil Nadu, totaling ₹2.37 crore for the financial year 2021-22. The pharmaceutical company disclosed this development in compliance with SEBI listing regulations on 20th February 2026.

Tax Demand Breakdown

The order issued by the Commercial Tax Officer presents a comprehensive demand structure across multiple components:

Nature of Dispute

The tax controversy stems from Input Tax Credit (ITC) claims related to FY 2020-21 that were subsequently claimed in FY 2021-22. The Commercial Tax Officer dismissed the company's submissions and reconciliations regarding the eligibility of these ITC claims, leading to the substantial tax demand.

Timeline and Receipt Details

The order was originally dated 30th December 2025, but Sanofi India received the communication on 19th February 2026. This timeline indicates a significant delay between the order issuance and the company's receipt of the official communication.

Company's Response Strategy

Sanofi India has indicated its intention to challenge the order through appropriate legal channels. The company stated it would make an appeal before the appellate authorities, suggesting confidence in its position regarding the ITC claims that were disputed by the tax officer.

Regulatory Compliance

The disclosure was made under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, demonstrating the company's commitment to transparency with stakeholders regarding material developments that could impact its operations.

Sanofi India Limited has announced a key change in its senior management team with the resignation of Mr. Suresh Babu, who served as Sales & Customer Engagement Head – Diabetes. The pharmaceutical company disclosed this development in compliance with regulatory requirements on February 12, 2026.

Resignation Details

Mr. Suresh Babu tendered his resignation from the services of the company effective from the close of business on February 12, 2026. The resignation was submitted to pursue other opportunities outside Sanofi, marking the end of his tenure as a Senior Management Personnel of the company.

Regulatory Compliance

The company has fulfilled its disclosure obligations under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The announcement was made to both BSE Limited and The National Stock Exchange of India Limited, ensuring transparency with stakeholders and regulatory authorities.

Transition Process

According to the resignation correspondence, Mr. Babu initially proposed February 28 as his last working day to allow for proper handover and transition. However, the final arrangement resulted in his departure on February 12, 2026, after completing the necessary handover procedures. The departing executive expressed commitment to ensuring a smooth transition with all details for business continuity.

Corporate Documentation

The disclosure was signed by Haresh Vala, Company Secretary and Compliance Officer, and includes comprehensive documentation as required under SEBI regulations. The company has also uploaded this information on its official website for stakeholder access and transparency.